Enclex 60 Injection (Enoxaparin)

Description

Enclex 60 Injection (Enoxaparin) — Complete Clinical and Patient Information Guide

Product Overview

Enclex 60 Injection (Enoxaparin) contains Enoxaparin Sodium 60mg as its active pharmaceutical ingredient, belonging to the low molecular weight heparin (LMWH) — anti-Xa predominant anticoagulant. It is clinically indicated for deep vein thrombosis (DVT) prophylaxis (surgical and medical patients); DVT and pulmonary embolism treatment; unstable angina and NSTEMI (with antiplatelet therapy); post-cardiac surgical anticoagulation bridge therapy. This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established cardiovascular clinical guidelines.

Enclex 60mg provides Enoxaparin 60mg, a low molecular weight heparin anticoagulant used in some of the most critical clinical situations in cardiovascular medicine — acute coronary syndromes, venous thromboembolism, and post-cardiac surgery anticoagulation. LMWH therapy with predictable pharmacokinetics has largely replaced unfractionated heparin for these indications, allowing safer outpatient anticoagulation for DVT/PE and consistent anticoagulation in unstable angina/NSTEMI.

About Enclex 60mg and Its Active Ingredient

Enoxaparin Sodium 60mg is the pharmacologically active compound in Enclex 60mg. Cardiovascular medications are among the most safety-critical drugs prescribed — interactions with other heart medications, anticoagulants, and antihypertensives can have life-threatening consequences, and abrupt discontinuation of certain cardiac drugs (beta-blockers, anticoagulants) without medical guidance can precipitate dangerous rebound phenomena. All cardiovascular pharmacotherapy decisions require specialist or physician oversight, with regular monitoring and dose optimisation based on clinical response, ECG findings, blood pressure recordings, and relevant biochemical parameters.

Mechanism of Action

Enoxaparin sodium is a low molecular weight heparin (LMWH) produced by depolymerisation of unfractionated heparin — yielding oligosaccharide fragments with a mean molecular weight of approximately 4,500 daltons. Enoxaparin’s anticoagulant mechanism is mediated through potentiation of antithrombin III (AT-III): enoxaparin binds AT-III through a specific pentasaccharide sequence, inducing a conformational change that dramatically accelerates AT-III’s inhibition of clotting factors. Critically, enoxaparin has a preferential anti-factor Xa activity (approximately 3:1 anti-Xa:anti-IIa activity ratio) compared to unfractionated heparin (1:1 ratio) — producing effective anticoagulation while generating less thrombin inhibition. This pharmacodynamic profile results in: predictable anticoagulant response allowing weight-adjusted subcutaneous dosing without routine aPTT monitoring; lower risk of heparin-induced thrombocytopenia (HIT) than UFH; once or twice-daily subcutaneous administration (no IV infusion required in most indications); and minimal protein binding providing consistent, predictable pharmacokinetics. Enoxaparin is used for DVT prophylaxis (40mg once daily SC), DVT/PE treatment (1mg/kg twice daily), unstable angina/NSTEMI (1mg/kg twice daily), and post-cardiac surgery anticoagulation.

A clear understanding of the pharmacological mechanism helps explain the clinical requirements: why timing, dose titration, monitoring, drug interactions, and contraindications exist. Healthcare providers use mechanistic knowledge to individualise therapy, anticipate interactions, and monitor for treatment response and toxicity.

Clinical Indications

Enclex 60 Injection (Enoxaparin) is clinically indicated for:

• Primary indication: deep vein thrombosis (DVT) prophylaxis (surgical and medical patients); DVT and pulmonary embolism treatment; unstable angina and NSTEMI (with antiplatelet therapy); post-cardiac surgical anticoagulation bridge therapy
• Specialist assessment required: Cardiovascular drug therapy must be initiated and monitored by a qualified cardiologist, physician, or specialist. Self-diagnosis and self-treatment of cardiac conditions is dangerous and may delay life-saving treatment.

Dosage and Administration

Administered subcutaneously (SC) by healthcare professionals or trained patients. DVT prophylaxis (general surgery/medical): 60mg SC once daily. DVT/PE treatment: 1mg/kg SC twice daily (or 1.5mg/kg once daily). NSTEMI: 1mg/kg SC twice daily + antiplatelet therapy for up to 8 days. 60mg (60mg/0.6ml) pre-filled syringes for precise dosing.

Never adjust the dose or stop cardiovascular medications without consulting your prescribing physician. Abrupt withdrawal of beta-blockers, anticoagulants, and anti-anginal drugs can cause dangerous rebound phenomena including angina exacerbation, myocardial infarction, and thromboembolic events.

Who Should Use Enclex 60mg

Enclex 60mg is indicated for adult patients in whom the relevant cardiovascular condition has been confirmed by clinical assessment and appropriate investigations (ECG, echocardiogram, cardiac biomarkers, blood pressure recording, coagulation studies as applicable) and in whom this specific pharmacological approach has been determined to be clinically appropriate after benefit-risk assessment.

Contraindications

Active major bleeding (absolute). Severe thrombocytopenia. History of HIT (heparin-induced thrombocytopenia) — cross-reactivity with LMWH is variable but generally avoid all heparins in confirmed HIT unless no alternative; use fondaparinux or argatroban. Severe renal impairment (eGFR <30ml/min for full therapeutic doses — dose reduction required; use UFH instead for very severe impairment). Hypersensitivity to enoxaparin, heparin, or pork products.

Drug Interactions

Antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor): significantly increase bleeding risk when combined with enoxaparin — standard combination in ACS under clinical monitoring. Thrombolytics: additive haemorrhage risk — timing of enoxaparin around thrombolysis requires specialist guidance. NSAIDs: increased bleeding risk. Vitamin K antagonists (warfarin): bridging protocols require careful timing and monitoring of both INR and anti-Xa activity.

Cardiovascular drugs have numerous clinically significant, potentially dangerous drug interactions. A comprehensive medication review by a cardiologist or clinical pharmacist is essential before initiating or changing any cardiac medication. Patients must inform all healthcare providers (including dentists, surgeons, and emergency physicians) of all their cardiovascular medications.

Adverse Effects

Common: Injection site bruising, haematoma, and pain (subcutaneous). Minor bleeding at venepuncture sites. Uncommon: Significant bleeding (GI, intracranial, retroperitoneal — risk proportional to dose and patient bleeding risk factors). Heparin-induced thrombocytopenia (HIT) — rare with LMWH (~0.1–0.2% vs 1–5% with UFH) but monitor platelet count at baseline and every 2–3 days with therapeutic doses. Rare: Osteoporosis with prolonged therapy (>3 months). Hyperkalaemia (through aldosterone inhibition). Skin necrosis at injection sites (rare). Anaphylaxis.

Special Population Considerations

Renal dose adjustment is essential: Enoxaparin is renally excreted — in significant renal impairment (eGFR <30ml/min), standard therapeutic doses accumulate and cause bleeding. Dose reduction and/or anti-Xa monitoring are required. For prophylactic doses in renal impairment, reduce to 20mg daily. For therapeutic doses, specialist guidance is essential. Injection technique: Inject SC into the anterolateral abdomen (L-shaped area, 5cm from umbilicus — not into umbilicus itself). Do not rub after injection. Alternate sides. Pre-filled syringes should be used at room temperature — remove from refrigerator 20–30 minutes before use for comfort. HIT monitoring: Check platelet count at baseline and every 2–3 days in the first 2 weeks of LMWH therapy — particularly in surgical/orthopaedic patients at highest HIT risk.

Storage and Handling

Store Enclex 60mg at room temperature (15–25°C) in a dry location away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use beyond the printed expiry date. Nitroglycerin preparations require special storage in airtight glass containers away from heat — plastic and light degrade GTN. Enoxaparin: store at room temperature; do not freeze.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next scheduled dose. Never double-dose. Do not stop beta-blockers, anticoagulants, or anti-anginal medications abruptly without medical advice.

Q: How do I give myself an enoxaparin injection?
A: Wash hands thoroughly. Sit or lie down. The injection site is the anterolateral abdominal fat — approximately 5cm from either side of the umbilicus. Pinch a fold of abdominal skin between thumb and forefinger. Insert the pre-filled syringe needle at a 90-degree angle through the skin fold. Depress the plunger steadily and completely. Withdraw needle and release skin fold. Do NOT rub the injection site. Alternate sides with each injection.

Evidence Base and Cardiovascular Guidelines

The active ingredient in Enclex 60mg has been evaluated in landmark randomised controlled trials and is supported by major international cardiovascular guidelines including those from the European Society of Cardiology (ESC), American College of Cardiology/American Heart Association (ACC/AHA), American Heart Association, National Institute for Health and Care Excellence (NICE), and relevant national cardiovascular specialist bodies. These guidelines represent evidence-based consensus on optimal pharmacological management of cardiovascular conditions and are regularly updated as new clinical evidence emerges.

Cardiovascular disease management has undergone transformative advances over the past three decades — from the landmark MERIT-HF, CAPRICORN, and EMPHASIS-HF trials establishing guideline-directed medical therapy for heart failure, to the COURAGE trial for stable angina, EINSTEIN for anticoagulation, and ADVANCE-HF for newer agents. Patients benefit most when their individual pharmacotherapy aligns with current evidence-based guidelines.

Patient Counselling Points

• Never stop abruptly: Beta-blockers, anti-anginal drugs, and anticoagulants must never be stopped suddenly without medical guidance — abrupt withdrawal can trigger angina rebound, myocardial infarction, arrhythmia, or thromboembolic events.
• Carry a medication list: All patients on cardiovascular drugs should carry a current medication list for any medical encounter — including surgical, dental, and emergency care. Drug interactions in cardiovascular patients can be life-threatening.
• Regular monitoring: Blood pressure, ECG, renal function, electrolytes (for diuretics), INR (for warfarin), platelet count (for heparins), and cardiac biomarkers as appropriate should be monitored at intervals determined by your cardiologist.
• Lifestyle integration: Pharmacotherapy delivers best results alongside appropriate lifestyle modification: Mediterranean diet, regular aerobic exercise, smoking cessation, moderate alcohol, sodium restriction for hypertension and heart failure.

Cardiovascular Disease Context and Clinical Management Principles

Cardiovascular disease (CVD) remains the leading cause of death globally, responsible for approximately 18 million deaths annually — representing 32% of all global mortality. Coronary artery disease, heart failure, hypertension, stroke, and peripheral arterial disease collectively impose an enormous burden of mortality, morbidity, and reduced quality of life worldwide. The last five decades have witnessed transformative advances in cardiovascular pharmacotherapy — from the introduction of beta-blockers and ACE inhibitors, through the development of statins and thrombolytics, to the current era of guideline-directed medical therapy with proven mortality-reducing agents for heart failure, and novel anticoagulants revolutionising stroke prevention in atrial fibrillation.

Effective cardiovascular disease management requires integration of pharmacological therapy with lifestyle modification (Mediterranean diet, regular aerobic exercise, smoking cessation, alcohol moderation, sodium restriction), risk factor control (blood pressure, lipid management, glycaemic control, weight management), and appropriate interventional or surgical procedures where indicated. Pharmacotherapy alone, without lifestyle integration and risk factor management, provides suboptimal benefit — drugs and lifestyle modification are synergistic, not alternative, approaches.

Hypertension: The Silent Cardiovascular Risk Factor

Hypertension affects approximately 1.28 billion adults worldwide, yet only 21% of hypertensive adults have their blood pressure adequately controlled. Uncontrolled hypertension is the leading modifiable risk factor for stroke, coronary artery disease, heart failure, renal failure, and peripheral arterial disease. The relationship between blood pressure and cardiovascular risk is continuous — even high-normal blood pressure (130–139/85–89 mmHg) carries increased cardiovascular risk compared to optimal levels.

Current international guidelines (ESC/ESH, ACC/AHA, NICE) recommend initial drug therapy for hypertension with one of three evidence-based drug classes: angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); calcium channel blockers (CCBs); or thiazide/thiazide-like diuretics. Most patients with stage 2 hypertension (≥160/100 mmHg) require combination therapy from initial diagnosis. Fixed-dose combination tablets — such as those in this product range — improve adherence and simplify therapy for patients requiring multiple agents.

Angina Pectoris: Management Principles

Stable angina pectoris affects over 110 million people globally and represents myocardial ischaemia occurring predictably with exertion or emotional stress, relieved by rest or sublingual nitroglycerin within minutes. The management goal is threefold: symptom relief, prevention of disease progression and MI, and improvement of quality of life. First-line symptomatic therapy uses beta-blockers and/or calcium channel blockers as rate-limiting or vasodilatory agents; long-acting nitrates or nicorandil are added when first-line therapy is insufficient. For resistant symptoms, trimetazidine or ivabradine (when HR remains elevated) provide additional anti-anginal mechanisms. When pharmacological therapy fails to control symptoms adequately, coronary revascularisation (PCI or CABG) should be considered.

Quality Standards and Evidence Base

The active ingredients in products in this range have been evaluated in landmark randomised controlled trials that form the foundation of evidence-based cardiovascular medicine: MERIT-HF (metoprolol succinate in HFrEF), CAPRICORN and COPERNICUS (carvedilol in post-MI LV dysfunction and HFrEF), BEAUTIFUL (ivabradine in stable CAD), SIGNIFY (ivabradine in stable angina), EINSTEIN (enoxaparin in VTE), EXTRACT-TIMI 25 (enoxaparin in STEMI), and IONA (nicorandil in stable angina). Major cardiovascular guidelines from the ESC, ACC/AHA, and NICE incorporate these drugs into evidence-based treatment algorithms based on the totality of this evidence.

Products are manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities, ensuring consistent quality, identity, strength, and purity. Patients should always obtain prescription cardiovascular medications from licensed pharmacies with valid prescriptions to ensure receipt of authentic, properly stored, quality-assured products.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed cardiology literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified cardiologist, physician, or pharmacist. Cardiovascular drug therapy decisions must be individualised by a licensed healthcare provider with full knowledge of the patient’s cardiac status, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of cardiovascular conditions can be dangerous and life-threatening. Always consult a qualified cardiologist or physician before starting, changing, or stopping any cardiovascular medication.